{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:12:42Z","timestamp":1790230362536,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.bcmd.2009.02.006","type":"journal-article","created":{"date-parts":[[2009,4,7]],"date-time":"2009-04-07T06:19:02Z","timestamp":1239085142000},"page":"58-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Differences in response to fetal hemoglobin induction therapy in \u03b2-thalassemia and sickle cell disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Hassana","family":"Fathallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George F.","family":"Atweh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2009.02.006_bib1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease","volume":"337","author":"Bunn","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2009.02.006_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0950-3536(98)80072-3","article-title":"Pathophysiology of thalassaemia","volume":"11","author":"Weatherall","year":"1998","journal-title":"Bailliere's Clin. Haematol."},{"key":"10.1016\/j.bcmd.2009.02.006_bib3","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/adc.67.4.517","article-title":"Fetal haemoglobin and early manifestations of homozygous sickle cell disease","volume":"67","author":"Bailey","year":"1992","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bcmd.2009.02.006_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-3476(81)80529-X","article-title":"Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood","volume":"98","author":"Stevens","year":"1981","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bcmd.2009.02.006_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0889-8588(18)30422-2","article-title":"Delta beta thalassemia and hereditary persistence of fetal hemoglobin","volume":"5","author":"Bollekens","year":"1991","journal-title":"Hematol.\/Oncol. Clin. North Am."},{"key":"10.1016\/j.bcmd.2009.02.006_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00062752-199502020-00001","article-title":"Natural history and determinants of clinical severity of sickle cell disease","volume":"2","author":"Serjeant","year":"1995","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bcmd.2009.02.006_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1196\/annals.1345.029","article-title":"Pharmacological induction of fetal hemoglobin: why haven't we been more successful in thalassemia?","volume":"1054","author":"Fathallah","year":"2005","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bcmd.2009.02.006_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1172\/JCI30920","article-title":"Sickle cell disease: old discoveries, new concepts, and future promise","volume":"117","author":"Frenette","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2009.02.006_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0022-3476(05)83304-9","article-title":"Pharmacologic treatment of thalassemia intermedia with hydroxyurea","volume":"125","author":"Hajjar","year":"1994","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bcmd.2009.02.006_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1749-6632.1998.tb10466.x","article-title":"Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis","volume":"850","author":"Ikuta","year":"1998","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bcmd.2009.02.006_bib11","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJM198212093072401","article-title":"5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia","volume":"307","author":"Ley","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2009.02.006_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/blood.V62.2.370.370","article-title":"5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia","volume":"62","author":"Ley","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2009.02.006_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1749-6632.1985.tb17189.x","article-title":"Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia","volume":"445","author":"Nienhuis","year":"1985","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bcmd.2009.02.006_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1749-6632.1998.tb10469.x","article-title":"Hydroxyurea therapy in thalassemia","volume":"850","author":"Loukopoulos","year":"1998","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.bcmd.2009.02.006_bib15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1182\/blood.V69.1.109.109","article-title":"Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia","volume":"69","author":"Charache","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2009.02.006_bib16","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.V82.7.2203.2203","article-title":"Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia","volume":"82","author":"Fibach","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2009.02.006_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI111731","article-title":"5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin","volume":"75","author":"Humphries","year":"1985","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcmd.2009.02.006_bib18","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2007-02-076091","article-title":"Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin","volume":"110","author":"Fathallah","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2009.02.006_bib19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bcmd.2007.08.001","article-title":"Epigenetic analysis of the human alpha- and beta-globin gene clusters","volume":"40","author":"Fathallah","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2009.02.006_bib20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0037-1963(01)90031-9","article-title":"Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia","volume":"38","author":"Atweh","year":"2001","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2009.02.006_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1365-2141.1995.tb05584.x","article-title":"Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis","volume":"90","author":"Zeng","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2009.02.006_bib22","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2004-02-0454","article-title":"Butyrate increases the efficiency of translation of gamma-globin mRNA","volume":"105","author":"Weinberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2009.02.006_bib23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V95.3.863.003k12_863_869","article-title":"Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells","volume":"95","author":"Smith","year":"2000","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979609000564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979609000564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:25:41Z","timestamp":1761049541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979609000564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S1079979609000564"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2009.02.006","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differences in response to fetal hemoglobin induction therapy in \u03b2-thalassemia and sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2009.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}